Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis

Hepatology

Volumn 49, Issue 2, 2009, Pages 513-522

  Midorikawa, Yutaka ^a,b,d   Yamamoto, Shogo ^a   Tsuji, Shingo ^a   Kamimura, Naoko ^a   Ishikawa, Shumpei ^a   Igarashi, Hisaki ^c   Makuuchi, Masatoshi ^b   Kokudo, Norihiro ^b   Sugimura, Haruhiko ^c   Aburatani, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TEIKYO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN CSMD1; TUMOR PROTEIN; UNCLASSIFIED DRUG; DNA; RNA;

ALLELIC IMBALANCE; ARTICLE; CANCER GROWTH; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME ADDITION; CHROMOSOME DELETION; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CPG ISLAND; DECISION TREE; DNA METHYLATION; DNA MICROARRAY; EARLY CANCER; GENE EXPRESSION; GENE LOCUS; GENOTYPE; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; CHROMOSOME 5; CHROMOSOME 8; DISEASE COURSE; GENE DELETION; GENETIC VARIABILITY; GENETICS; HOMOZYGOTE; ISOLATION AND PURIFICATION; LIVER CELL; LIVER DISEASE; LIVER RESECTION; LIVER TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALLELIC IMBALANCE; CARCINOMA, HEPATOCELLULAR; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 8; DISEASE PROGRESSION; DNA, NEOPLASM; GENETIC VARIATION; HEPATECTOMY; HEPATOCYTES; HOMOZYGOTE; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SEQUENCE DELETION;

EID: 61949261498     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22698     Document Type: Article

References (48)

1. Kojiro M. 'Nodule-in-nodule' appearance in hepatocellular carcinoma: Its significance as a morphologic marker of dedifferentiation. Intervirology 2004;47:179-183.
2. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepato-carcinogenesis: Adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991;22:172-178.
3. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. HEPATOLOGY 1998;28:1241-1246.
4. Nam SW, Lee JH, Noh JH, Lee SN, Kim SY, Lee SH, et al. Comparative analysis of expression profiling of early-stage carcinogenesis using nodule-in-nodule-type hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2006;18:239-247.
5. Midorikawa Y, Tsutsumi S, Taniguchi H, Ishii M, Kobune Y, Kodama T, et al. Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn J Cancer Res 2002; 93:636-643.
6. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, et al. Expression profiling in multistage hepatocarcinogenesis: Identification of HSP70 as a molecular marker of early hepatocellular carcinoma. HEPATOLOGY 2003;37:198-207.
7. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992;258:818-821.
8. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-211.
9. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002;99:12963-12968.
10. Bignell GR, Huang J, Greshock J, Watt S, Butler A, West S, et al. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res 2004;14:287-295.
11. Ishikawa S, Komura D, Tsuji S, Nishimura K, Yamamoto S, Panda B, et al. Allelic dosage analysis with genotyping microarrays. Biochem Biophys Res Commun 2005;333:1309-1314.
12. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005;65:6071-6079.
13. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004;64:3060-3071.
14. Midorikawa Y, Yamamoto S, Ishikawa S, Kamimura N, Igarashi H, Sugimura H, et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene 2006;25:5581-5590.
15. Midorikawa Y, Tsutsumi S, Nishimura K, Kamimura N, Kano M, Sakamoto H, et al. Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma. Cancer Res 2004;64:7263-7270.
16. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005;65:5561-5570.
17. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
18. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-6845.
19. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
20. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-597.
21. Rozier L, El-Achkar E, Apiou F, Debatisse M. Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: Possible association with an inherited disease and cancer. Oncogene 2004;23:6872-6880.
22. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A 2003;100:5956-5961.
23. Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001;61:8068-8073.
24. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140-2145.
25. Freedman GM, Hanlon AL, Fowble BL, Anderson PR, Nicolaou N. Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. J Clin Oncol 2002;20:4015-4021.
26. Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25:1129-1134.
27. Delen D, Walker G, Kadam A. Predicting breast cancer survivability: A comparison of three data mining methods. Artif. Intell Med 2005;34:113-127.
28. Jiang F, Desper R, Papadimitriou CH, Schaffer AA, Kallioniemi OP, Richter J, et al. Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data. Cancer Res 2000;60:6503-6509.
29. Desper R, Jiang F, Kallioniemi OP, Moch H, Papadimitriou CH, Schaffer AA. Distance-based reconstruction of tree models for oncogenesis. J Comput Biol 2000;7:789-803.
30. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
31. Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003;103:455-465.
32. Kitayama Y, Igarashi H, Watanabe F, Maruyama Y, Kanamori M, Sugimura H. Nonrandom chromosomal numerical abnormality predicting prognosis of gastric cancer: A retrospective study of 51 cases using pathology archives. Lab Invest 2003;83:1311-1320.
33. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-9826.
34. Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: An Eastern point of view. Liver Transpl 2004;10:S3-S8.
35. Japan Liver Cancer Society Group. General rules for the clinical and pathological study of primary liver cancer: 2nd ed. Tokyo: Kanchura; 2003:15-16.
36. Nishida N, Fukuda Y, Kokuryu H, Sadamoto T, Isowa G, Honda K, et al. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer 1992;51:862-868.
37. Ho MK, Lee JM, Chan CK, Ng IO. Allelic alterations in nontumorous liver tissues and corresponding hepatocellular carcinomas from chinese patients. Hum Pathol 2003;34:699-705.
38. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: Relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999;154:37-43.
39. Ashida K, Kishimoto Y, Nakamoto K, Wada K, Shiota G, Hirooka Y, et al. Loss of heterozygosity of the retinoblastoma gene in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol 1997;123: 489-495.
40. Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Hirohashi S. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis. Cancer Lett 2000;148:73-80.
41. Maggioni M, Coggi G, Cassani B, Bianchi P, Romagnoli S, Mandelli A, et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies. HEPATOLOGY 2000;32:942-946.
42. Roncalli M, Bianchi P, Grimaldi GC, Ricci D, Laghi L, Maggioni M, et al. Fractional allelic loss in non-end-stage cirrhosis: Correlations with hepatocellular carcinoma development during follow-up. HEPATOLOGY 2000;31: 846-850.
43. Nagai H, Terada Y, Tajiri T, Yabe A, Onda M, Nagahata T, et al. Characterization of liver-cirrhosis nodules by analysis of gene-expression profiles and patterns of allelic loss. J Hum Genet 2004;49:246-255.
44. Yamada T, De Souza AT, Finkelstein S, Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci U S A 1997;94:10351-10355.
45. Sun M, Eshleman JR, Ferrell LD, Jacobs G, Sudilovsky EC, Tuthill R, et al. An early lesion in hepatic carcinogenesis: Loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. HEPATOLOGY 2001;33:1415-1424.
46. Sun PC, Uppaluri R, Schmidt AP, Pashia ME, Quant EC, Sunwoo JB, et al. Transcript map of the 8p23 putative tumor suppressor region. Genomics 2001;75:17-25.
47. Toomes C, Jackson A, Maguire K, Wood J, Gollin S, Ishwad C, et al. The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes Chromosomes Cancer 2003;37:132-140.
48. Richter TM, Tong BD, Scholnick SB. Epigenetic inactivation and aberrant transcription of CSMD1 in squamous cell carcinoma cell lines. Cancer Cell Int 2005;5:29.